<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04596319</url>
  </required_header>
  <id_info>
    <org_study_id>AP-PA02-101</org_study_id>
    <nct_id>NCT04596319</nct_id>
  </id_info>
  <brief_title>Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis</brief_title>
  <acronym>SWARM-Pa</acronym>
  <official_title>A Phase 1b/2a, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of AP-PA02 Multi-Phage Therapeutic Candidate for Inhalation in Subjects With Cystic Fibrosis and Chronic Pulmonary Pseudomonas Aeruginosa (Pa) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Armata Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cystic Fibrosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Armata Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1b/2a, double-blind, randomized, placebo-controlled, single and multiple ascending dose&#xD;
      study to evaluate the safety, tolerability and phage recovery profile of AP-PA02&#xD;
      multi-bacteriophage therapeutic candidate administered by inhalation in subjects with cystic&#xD;
      fibrosis and chronic pulmonary Pseudomonas aeruginosa (PA) infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of two parts. Subjects with Cystic Fibrosis and chronic pulmonary&#xD;
      Pseudomonas aeruginosa (PA) infection will be enrolled in either Part 1 (single-ascending&#xD;
      dose cohorts) or Part 2 (multiple-ascending dose cohorts).&#xD;
&#xD;
      Part 1 will evaluate single doses of AP-PA02 at three ascending dose levels, administered by&#xD;
      inhalation. Treatment assignment will be randomized, double-blind, placebo-controlled in each&#xD;
      of three ascending dose cohorts. Part 2 will also be double-blinded, randomized, placebo&#xD;
      controlled, and will evaluate the safety and efficacy of multiple doses of AP-PA02 in each of&#xD;
      three ascending dose level cohorts.&#xD;
&#xD;
      Subjects in both Parts 1 and 2 will be followed for approximately 4 weeks and evaluated for&#xD;
      safety, tolerability, phage titer profile and immunogenicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 22, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, placebo-controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events (Safety and Tolerability) of single and multiple doses of AP-PA02 administered by inhalation</measure>
    <time_frame>Day 1 pre-dose through End of Study Visit (Day 29 for SAD, Day 31 for MAD)</time_frame>
    <description>Incidence and severity of treatment-emergent adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 2 (MAD) Only: Explore P. aeruginosa recovery in sputum following multiple doses of AP-PA02 administered by inhalation</measure>
    <time_frame>Baseline (Day -1) through Visit 7 (Day 17)</time_frame>
    <description>Change in P. aeruginosa colony-forming units (CFU) per gram of sputum</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Pseudomonas Aeruginosa</condition>
  <condition>Pseudomonas</condition>
  <condition>Lung Infection</condition>
  <condition>Lung Infection Pseudomonal</condition>
  <arm_group>
    <arm_group_label>AP-PA02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-pseudomonal bacteriophage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inactive isotonic solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AP-PA02</intervention_name>
    <description>Bacteriophage administered via inhalation</description>
    <arm_group_label>AP-PA02</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive Placebo administered via inhalation</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 years old&#xD;
&#xD;
          -  Body mass index (BMI) of ≥ 18 kg/m2&#xD;
&#xD;
          -  Documented diagnosis of CF&#xD;
&#xD;
          -  Evidence of chronic pulmonary Pseudomonas aeruginosa infection&#xD;
&#xD;
          -  Willing to undergo sputum induction procedures at designated study visits, and willing&#xD;
             to provide expectorated sputum samples at all other timepoints (for subjects who are&#xD;
             able to expectorate)&#xD;
&#xD;
          -  FEV1 ≥ 60% of predicted normal [per Global Lung Function Initiative (GLI) standards]&#xD;
             at Screening&#xD;
&#xD;
          -  Adequate renal function&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Recent significant weight loss&#xD;
&#xD;
          -  Abnormal vital signs at Screening&#xD;
&#xD;
          -  History of prolonged QT syndrome&#xD;
&#xD;
          -  Use of supplemental oxygen during the day at rest&#xD;
&#xD;
          -  Abnormal liver function tests greater than 3X the upper limit of normal (ULN)&#xD;
&#xD;
          -  Recent oral or IV antibiotics received for acute pulmonary exacerbation. Inhaled&#xD;
             antibiotic use for chronic suppression of P. aeruginosa is acceptable.&#xD;
&#xD;
          -  Recent clinically significant infection requiring systemic antimicrobial therapy&#xD;
&#xD;
          -  Currently receiving anti-pseudomonal antibiotic treatment for acute sinusitis.&#xD;
&#xD;
          -  Currently receiving systemic corticosteroids&#xD;
&#xD;
          -  Currently receiving treatment for active infection with nontuberculous mycobacteria&#xD;
             (NTM), Staphylococcus aureus, or Burkholderia cepacia complex lung infection&#xD;
&#xD;
          -  Currently receiving treatment for aspergillosis or ABPA (allergic bronchopulmonary&#xD;
             aspergillosis)&#xD;
&#xD;
          -  Initiation of a CFTR potentiator/corrector therapy, such as Trikafta®, less than 90&#xD;
             days prior to Screening&#xD;
&#xD;
          -  Acquired or primary immunodeficiency syndromes&#xD;
&#xD;
          -  Active pulmonary malignancy (primary or metastatic)&#xD;
&#xD;
          -  History of lung transplantation&#xD;
&#xD;
          -  Recent hemoptysis&#xD;
&#xD;
          -  Female pregnant or breastfeeding&#xD;
&#xD;
          -  Heavy smoker&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mina Pastagia, MD, MS</last_name>
    <role>Study Director</role>
    <affiliation>Armata Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vicki White, BS</last_name>
    <phone>310-633-4566</phone>
    <email>vwhite@armatapharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pierre Kyme, PhD</last_name>
    <phone>310-665-2928</phone>
    <phone_ext>234</phone_ext>
    <email>pkyme@armatapharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Reyes</last_name>
      <email>mareyes@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Keens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Grube</last_name>
      <phone>813-844-8624</phone>
      <email>klgrube@usf.edu</email>
    </contact>
    <investigator>
      <last_name>Timothy Floreth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's Cystic Fibrosis Center of Idaho</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lejla Godusevic</last_name>
      <phone>208-381-4717</phone>
      <email>godusevl@slhs.org</email>
    </contact>
    <investigator>
      <last_name>Perry Brown, MD, FAAP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Nelson</last_name>
      <email>rachel.nelson@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Manu Jain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Teresi</last_name>
      <email>mary-teresi@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Tahuanty Pena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shivani Patel</last_name>
      <email>spate156@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Natalie West, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Fowler</last_name>
      <email>Robert.Fowler@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Henry Dorkin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Halina Malveaux, RN BSN</last_name>
      <email>Malveaha@rwjms.rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Sugeet Jagpal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terri Johnson</last_name>
      <email>Terri.Johnson@nationwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Karen McCoy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Selena Herring</last_name>
      <email>selena.herring@pennmedicine.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Dorgan, MD</last_name>
      <email>Daniel.Dorgan@pennmedicine.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Dorgan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Max Lento</last_name>
      <email>lento@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick Flume, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brijesh Patel</last_name>
      <email>Brijesh.Patel@vumc.org</email>
    </contact>
    <contact_backup>
      <last_name>James J Tolle, MD</last_name>
      <email>James.J.Tolle@vanderbilt.edu</email>
    </contact_backup>
    <investigator>
      <last_name>James J Tolle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Keller</last_name>
      <email>ashley.keller@utsouhtwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Raksha Jain, MD</last_name>
      <email>Raksha.Jain@UTSouthwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Raksha Jain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Conti</last_name>
      <email>miconti@medicine.washington.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher Goss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-9988</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophia Chiron-Stevens</last_name>
      <email>scstevens@medicine.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew T Braun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://armatapharma.com</url>
    <description>Armata Pharmaceuticals, Inc.</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 15, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>phage</keyword>
  <keyword>bacteriophage</keyword>
  <keyword>cystic fibrosis</keyword>
  <keyword>Pseudomonas</keyword>
  <keyword>Pseudomonas aeruginosa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Pseudomonas Infections</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

